Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
Published in
Therapeutics and Clinical Risk Management, June 2017
Pharmacology, Toxicology and Pharmaceutical Science
10
12%
Unspecified
5
6%
Economics, Econometrics and Finance
4
5%
Business, Management and Accounting
3
3%
Other
15
17%
Unknown
28
33%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 December 2020.
All research outputs
#5,449,088
of 25,382,440 outputs
Outputs from Therapeutics and Clinical Risk Management
#275
of 1,323 outputs
Outputs of similar age
#88,402
of 330,503 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#5
of 24 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,503 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.
